vs

Side-by-side financial comparison of NEOGENOMICS INC (NEO) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $173.1M, roughly 1.1× VARONIS SYSTEMS INC). On growth, VARONIS SYSTEMS INC posted the faster year-over-year revenue change (26.9% vs 11.1%). Over the past eight quarters, VARONIS SYSTEMS INC's revenue compounded faster (15.2% CAGR vs 6.5%).

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.

NEO vs VRNS — Head-to-Head

Bigger by revenue
NEO
NEO
1.1× larger
NEO
$186.7M
$173.1M
VRNS
Growing faster (revenue YoY)
VRNS
VRNS
+15.8% gap
VRNS
26.9%
11.1%
NEO
Faster 2-yr revenue CAGR
VRNS
VRNS
Annualised
VRNS
15.2%
6.5%
NEO

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
NEO
NEO
VRNS
VRNS
Revenue
$186.7M
$173.1M
Net Profit
$-108.0M
Gross Margin
43.3%
76.0%
Operating Margin
46.9%
-1.7%
Net Margin
-57.9%
Revenue YoY
11.1%
26.9%
Net Profit YoY
42.0%
EPS (diluted)
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEO
NEO
VRNS
VRNS
Q1 26
$186.7M
$173.1M
Q4 25
$190.2M
$173.4M
Q3 25
$187.8M
$161.6M
Q2 25
$181.3M
$152.2M
Q1 25
$168.0M
$136.4M
Q4 24
$172.0M
$158.5M
Q3 24
$167.8M
$148.1M
Q2 24
$164.5M
$130.3M
Net Profit
NEO
NEO
VRNS
VRNS
Q1 26
$-108.0M
Q4 25
$-27.8M
Q3 25
$-27.1M
$-29.9M
Q2 25
$-45.1M
$-35.8M
Q1 25
$-25.9M
$-35.8M
Q4 24
$-13.0M
Q3 24
$-17.7M
$-18.3M
Q2 24
$-18.6M
$-23.9M
Gross Margin
NEO
NEO
VRNS
VRNS
Q1 26
43.3%
76.0%
Q4 25
43.8%
78.9%
Q3 25
42.8%
78.2%
Q2 25
42.6%
79.5%
Q1 25
43.6%
78.7%
Q4 24
44.9%
83.6%
Q3 24
44.6%
83.8%
Q2 24
44.1%
82.8%
Operating Margin
NEO
NEO
VRNS
VRNS
Q1 26
46.9%
-1.7%
Q4 25
-7.1%
-17.5%
Q3 25
-14.4%
-22.2%
Q2 25
-26.3%
-24.0%
Q1 25
-16.6%
-32.1%
Q4 24
-10.7%
-11.1%
Q3 24
-12.6%
-16.0%
Q2 24
-13.3%
-22.1%
Net Margin
NEO
NEO
VRNS
VRNS
Q1 26
-57.9%
Q4 25
-16.0%
Q3 25
-14.4%
-18.5%
Q2 25
-24.9%
-23.5%
Q1 25
-15.4%
-26.2%
Q4 24
-8.2%
Q3 24
-10.5%
-12.4%
Q2 24
-11.3%
-18.4%
EPS (diluted)
NEO
NEO
VRNS
VRNS
Q1 26
$-0.13
Q4 25
$-0.23
Q3 25
$-0.26
Q2 25
$-0.32
Q1 25
$-0.32
Q4 24
$-0.12
Q3 24
$-0.16
Q2 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEO
NEO
VRNS
VRNS
Cash + ST InvestmentsLiquidity on hand
$146.1M
$179.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$828.8M
$453.5M
Total Assets
$1.3B
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEO
NEO
VRNS
VRNS
Q1 26
$146.1M
$179.3M
Q4 25
$159.6M
$883.7M
Q3 25
$164.1M
$671.3M
Q2 25
$154.7M
$770.9M
Q1 25
$346.2M
$567.6M
Q4 24
$367.0M
$529.0M
Q3 24
$362.0M
$844.8M
Q2 24
$355.1M
$582.5M
Total Debt
NEO
NEO
VRNS
VRNS
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
Q3 24
Q2 24
Stockholders' Equity
NEO
NEO
VRNS
VRNS
Q1 26
$828.8M
$453.5M
Q4 25
$836.6M
$598.7M
Q3 25
$838.3M
$604.8M
Q2 25
$854.0M
$341.5M
Q1 25
$888.3M
$367.7M
Q4 24
$902.3M
$455.7M
Q3 24
$908.2M
$428.6M
Q2 24
$915.9M
$458.6M
Total Assets
NEO
NEO
VRNS
VRNS
Q1 26
$1.3B
$1.6B
Q4 25
$1.4B
$1.8B
Q3 25
$1.4B
$1.7B
Q2 25
$1.4B
$1.6B
Q1 25
$1.6B
$1.6B
Q4 24
$1.6B
$1.7B
Q3 24
$1.6B
$1.5B
Q2 24
$1.6B
$1.1B
Debt / Equity
NEO
NEO
VRNS
VRNS
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEO
NEO
VRNS
VRNS
Operating Cash FlowLast quarter
$-8.1M
$55.0M
Free Cash FlowOCF − Capex
$49.0M
FCF MarginFCF / Revenue
28.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$118.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEO
NEO
VRNS
VRNS
Q1 26
$-8.1M
$55.0M
Q4 25
$1.3M
$24.7M
Q3 25
$8.9M
$33.4M
Q2 25
$20.3M
$21.3M
Q1 25
$-25.3M
$68.0M
Q4 24
$9.8M
$24.3M
Q3 24
$9.2M
$22.5M
Q2 24
$13.9M
$11.7M
Free Cash Flow
NEO
NEO
VRNS
VRNS
Q1 26
$49.0M
Q4 25
$-6.5M
$20.7M
Q3 25
$570.0K
$30.4M
Q2 25
$14.0M
$18.0M
Q1 25
$-29.8M
$65.7M
Q4 24
$-1.8M
$19.9M
Q3 24
$-1.6M
$21.3M
Q2 24
$814.0K
$10.9M
FCF Margin
NEO
NEO
VRNS
VRNS
Q1 26
28.3%
Q4 25
-3.4%
12.0%
Q3 25
0.3%
18.8%
Q2 25
7.7%
11.8%
Q1 25
-17.8%
48.1%
Q4 24
-1.0%
12.6%
Q3 24
-0.9%
14.4%
Q2 24
0.5%
8.4%
Capex Intensity
NEO
NEO
VRNS
VRNS
Q1 26
Q4 25
4.1%
2.3%
Q3 25
4.4%
1.8%
Q2 25
3.5%
2.2%
Q1 25
2.7%
1.7%
Q4 24
6.7%
2.7%
Q3 24
6.4%
0.8%
Q2 24
8.0%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEO
NEO

Segment breakdown not available.

VRNS
VRNS

SaaS$161.1M93%
Term license subscriptions$6.9M4%
Maintenance and services$5.2M3%

Related Comparisons